CEO O’Connell, CMO Siemers & CFO Zuga discuss the topline results from Acumen’s Phase 1 INTERCEPT-AD Trial in early Alzheimer’s Disease on a conference call to be held on July 17 at 8 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABOS:
- Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
- Cantor Fitzgerald healthcare analyst holds an analyst/industry conference call
- Acumen to present topline results from Phase 1 study of ACU193
- Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023